Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 738-747

  Spranger, Stefani ^a   Javorovic, Miran ^a   Bürdek, Maja ^a   Wilde, Susanne ^a   Mosetter, Barbara ^a   Tippmer, Stefanie ^a   Bigalke, Iris ^a   Geiger, Christiane ^a   Schendel, Dolores J ^a   Frankenberger, Bernhard ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CL 075; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; RESIQUIMOD; STAT1 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CANCER VACCINE; CYTOKINE; IMIDAZOLE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LIGAND; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; TLR3 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELL POLARITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MONOCYTE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; COCULTURE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; PHYSIOLOGY; SECRETION; SYNTHESIS; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL POLARITY; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; POLY I-C; QUINOLINES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; THIAZOLES; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 77956222584     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000060     Document Type: Article

References (48)

1. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138-147.
2. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306.
3. Mocikat, R., H. Braumüller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch, A. Bubeck, J. Louis, R. Mailhammer, G. Riethmüller, et al. 2003. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19: 561-569. (Pubitemid 37311437)
4. + T-cell-independent pathway for antitumor CTL induction. Blood 106: 338-344.
5. Karimi, K., J. E. Boudreau, K. Fraser, H. Liu, J. Delanghe, J. Gauldie, Z. Xing, J. L. Bramson, and Y. Wan. 2008. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN γ-producing NK cells. Mol. Ther. 16: 411-418.
6. Pallandre, J. R., K. Krzewski, R. Bedel, B. Ryffel, A. Caignard, P. S. Rohrlich, X. Pivot, P. Tiberghien, L. Zitvogel, J. L. Strominger, and C. Borg. 2008. Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. Blood 112: 4420-4424.
7. Jonuleit, H., U. Kühn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142.
8. Dauer, M., B. Obermaier, J. Herten, C. Haerle, K. Pohl, S. Rothenfusser, M. Schnurr, S. Endres, and A. Eigler. 2003. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170: 4069-4076.
9. Obermaier, B., M. Dauer, J. Herten, K. Schad, S. Endres, and A. Eigler. 2003. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol. Proced. Online 5: 197-203.
10. Dauer, M., V. Lam, H. Arnold, J. Junkmann, R. Kiefl, C. Bauer, M. Schnurr, S. Endres, and A. Eigler. 2008. Combined use of Toll-like receptor agonists and prostaglandin E2 in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J. Immunol. Methods 337: 97-105.
11. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J. Exp. Med. 179: 1109-1118.
12. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389-400.
13. Sato, K., H. Nagayama, K. Tadokoro, T. Juji, and T. A. Takahashi. 1999. Interleukin- 13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells. Exp. Hematol. 27: 326-336.
14. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
15. Schreibelt, G., J. Tel, K. H. Sliepen, D. Benitez-Ribas, C. G. Figdor, G. J. Adema, and I. J. de Vries. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. In press.
16. Philbin, V. J., and O. Levy. 2007. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem. Soc. Trans. 35: 1485-1491.
17. Gorden, K. B., K. S. Gorski, S. J. Gibson, R. M. Kedl, W. C. Kieper, X. Qiu, M. A. Tomai, S. S. Alkan, and J. P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174: 1259-1268.
18. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3: 499.
19. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
20. Förster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Müller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33.
21. Gunn, M. D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189: 451-460.
22. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200.
23. Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski. 2004. α - Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64: 5934-5937.
24. Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E. Bates, G. Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201: 1435-1446.
25. Roelofs, M. F., L. A. Joosten, S. Abdollahi-Roodsaz, A. W. van Lieshout, T. Sprong, F. H. van den Hoogen, W. B. van den Berg, and T. R. Radstake. 2005. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52: 2313-2322.
26. Zobywalski, A., M. Javorovic, B. Frankenberger, H. Pohla, E. Kremmer, I. Bigalke, and D. J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5: 18.
27. Schaft, N., J. Dörrie, P. Thumann, V. E. Beck, I. Müller, E. S. Schultz, E. Kämpgen, D. Dieckmann, and G. Schuler. 2005. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 174: 3087-3097.
28. Javorovic, M., H. Pohla, B. Frankenberger, T. Wölfel, and D. J. Schendel. 2005. RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol. Ther. 12: 734-743.
29. Wilde, S., D. Sommermeyer, B. Frankenberger, M. Schiemann, S. Milosevic, S. Spranger, H. Pohla, W. Uckert, D. H. Busch, and D. J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114: 2131-2139.
30. Dong, L. W., X. N. Kong, H. X. Yan, L. X. Yu, L. Chen, W. Yang, Q. Liu, D. D. Huang, M. C. Wu, and H. Y. Wang. 2008. Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. Mol. Immunol. 45: 3025-3035.
31. Takeda, K. 2005. Evolution and integration of innate immune recognition systems: the Toll-like receptors. J. Endotoxin Res. 11: 51-55. (Pubitemid 40533080)
32. Hornung, V., J. Ellegast, S. Kim, K. Brzózka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, et al. 2006. 5′- Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
33. Ohl, L., M. Mohaupt, N. Czeloth, G. Hintzen, Z. Kiafard, J. Zwirner, T. Blankenstein, G. Henning, and R. Förster. 2004. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21: 279-288.
34. Saeki, H., A. M. Moore, M. J. Brown, and S. T. Hwang. 1999. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 162: 2472-2475.
35. Jonuleit, H., E. Schmitt, K. Steinbrink, and A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22: 394-400.
36. Steinbrink, K., M. Wölfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-4780.
37. Toubi, E., and Y. Shoenfeld. 2004. Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity 37: 183-188.
38. Ito, T., R. Amakawa, and S. Fukuhara. 2002. Roles of Toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum. Immunol. 63: 1120-1125.
39. + T-cell function in melanoma patients. J. Clin. Oncol. 21: 3826-3835.
40. Gilliet, M., M. Kleinhans, E. Lantelme, D. Schadendorf, G. Burg, and F. O. Nestle. 2003. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102: 36-42.
41. 2 results in high interleukin- 12 production and cell migration. Cancer Immunol. Immunother. 57: 1589-1597.
42. Larangé, A., D. Antonios, M. Pallardy, and S. Kerdine-Römer. 2009. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 85: 673-683.
43. Koopman, L. A., H. D. Kopcow, B. Rybalov, J. E. Boyson, J. S. Orange, F. Schatz, R. Masch, C. J. Lockwood, A. D. Schachter, P. J. Park, and J. L. Strominger. 2003. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J. Exp. Med. 198: 1201-1212.
44. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Höfler, E. Guthann, U. Korthäuer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, et al. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170: 3637-3644.
45. Liu, J., A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304.
46. O'Shea, J. J. 1997. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7: 1-11.
47. Bauvois, B., J. Nguyen, R. Tang, C. Billard, and J. P. Kolb. 2009. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1. Biochem. Pharmacol. 78: 514-522.
48. Mazanet, M. M., and C. C. Hughes. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169: 3581-3588.